Liver Extracellular Matrices Bioactivated Hepatic Spheroids as a Model System for Drug Hepatotoxicity Evaluations
Authors:
- 8 August 2018
- journal article
- research article
- Published by Wiley in Advanced Biosystems
- Vol. 2 (10)
Abstract
Drug‐induced liver injury (DILI) is a leading cause of acute liver failure. A major obstacle in the prediction or evaluation of DILI is the lack of an experimental model(s) that recapitulates the stable and physiologically relevant liver functions and reflects accurately the level of drug hepatotoxicity. Native extracellular matrices that are secreted and maintained by resident cells are receiving great interest as biomaterials for cell culture and cell delivery. In this study, a hepatic spheroid model system, treated with cryopulverized liver biomatrix scaffolds (LBSs), is established for DILI investigations. The LBSs provide a liver‐specific microenvironment bioactivating metabolic traits paralleling those in vivo, resulting in the fact that LBS‐bioactivated model system shows enhancing liver‐specific functions (albumin secretion, urea synthesis, glycogen storage), cytochrome P450 enzymes (CYPs) metabolic activity, bile excretion, and increased expression of phase I and II metabolism enzymes, transporters, and nuclear receptors, collectively hypothesized to result from increased cell–cell and cell–matrix interactions. Toxicity assessments with LBS‐bioactivated hepatic spheroids reveal an improved sensitivity in identifying hepatotoxic compounds. In summary, using this model system, a simple but robust high‐throughput‐compatible methodology is developed, which shows great potential for use in toxicity screening assays, and represents an alternative to animal models for studying DILI.Keywords
Funding Information
- National Natural Science Foundation of China (31370990, 81730052)
This publication has 50 references indexed in Scilit:
- Emerging In Vitro Liver Technologies for Drug Metabolism and Inter-Organ InteractionsTissue Engineering Part B: Reviews, 2016
- Human Hepatic HepaRG Cells Maintain an Organotypic Phenotype with High Intrinsic CYP450 Activity/Metabolism and Significantly Outperform Standard HepG2/C3A Cells for Pharmaceutical and Therapeutic ApplicationsBasic & Clinical Pharmacology & Toxicology, 2016
- Unexpected low‐dose toxicity of the universal solvent DMSOThe FASEB Journal, 2013
- 3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity StudiesToxicological Sciences, 2013
- Transdifferentiation of hepatocyte‐like cells from the human hepatoma HepaRG cell line through bipotent progenitor†Hepatology, 2007
- Drug-Induced Liver InjuryDrug Safety, 2007
- Infection of a human hepatoma cell line by hepatitis B virusProceedings of the National Academy of Sciences, 2002
- Troglitazone (Rezulin) and hepatic injuryPharmacoepidemiology and Drug Safety, 2001
- Pemoline Hepatotoxicity and Postmarketing SurveillanceJournal of the American Academy of Child & Adolescent Psychiatry, 2001
- Acetaminophen‐induced hepatic injury: Protective role of glutathione in man and rationale for therapyClinical Pharmacology & Therapeutics, 1974